

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K/A**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 03, 2026**

---

**AVITA Medical, Inc.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39059**  
(Commission File Number)

**85-1021707**  
(IRS Employer  
Identification No.)

**28159 Avenue Stanford  
Suite 220  
Valencia, California**  
(Address of Principal Executive Offices)

**91355**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 661 367-9170**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

| Title of each class                        | Trading<br>Symbol(s) | Name of each exchange on which registered |
|--------------------------------------------|----------------------|-------------------------------------------|
| Common Stock, par value \$0.0001 per share | RCEL                 | The Nasdaq Stock Market LLC               |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

### Explanatory Note

This Current Report on Form 8-K/A (this "Amendment") amends the Current Report on Form 8-K filed by AVITA Medical, Inc. (the "Company") with the Securities and Exchange Commission on June 4, 2026 (the "Original Form 8-K"), which reported, among other things, the voting results of the Company's Annual Meeting of Stockholders held on June 3, 2026 (the "Meeting"). The sole purpose of this Amendment is to disclose, in accordance with Item 5.07(d) of Form 8-K, the Company's decision regarding how frequently it will conduct future stockholder advisory votes to approve the compensation of the Company's named executive officers. No other changes have been made to the Original Form 8-K.

#### Item 5.07 Submission of Matters to a Vote of Security Holders.

As previously disclosed in the Original Form 8-K, at the Meeting the Company's stockholders cast the following votes on an advisory basis regarding the frequency of future advisory votes on the compensation of the Company's named executive officers:

8. *Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation (Proposal 13)*: Stockholders voted in favor of the non-binding advisory vote to set the frequency of future advisory votes to approve the compensation of the Company's named executive officers. The votes regarding this proposal were as follows:

| Votes For |         |         | Abstentions | Broker Non-Votes |
|-----------|---------|---------|-------------|------------------|
| 1 Year    | 2 Years | 3 Years |             |                  |
| 9,545,151 | 924,743 | 650,252 | 581,759     | 3,890,542        |

Consistent with the recommendation of the Company's Board of Directors and the option receiving the highest number of votes cast by the Company's stockholders, the Board of Directors has determined that the Company will hold future advisory votes on the compensation of its named executive officers every year until the next required advisory vote on the frequency of such votes, which will occur no later than the Company's 2032 Annual Meeting of Stockholders.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVITA Medical, Inc.

Date: August 6, 2026

By: /s/ David O'Toole  
David O'Toole  
Chief Financial Officer

---

